New trial aims to give every blood cancer patient a donor
NCT ID NCT06809712
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether stem cell transplants from donors whose tissue type does not fully match the patient can be safe and effective for people with blood cancers who have no other donor options. About 29 adults aged 18-60 will receive chemotherapy followed by the transplant. The main goal is to see how many patients survive over time, while also tracking how well the new stem cells take hold.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
allogeneic hematopoietic stem cell transplant (donor stem cells) with chemotherapy drugs (busulfan, cyclophosphamide, fludarabine, semustine)
What this could lead to
If successful, this approach could provide a transplant option for blood cancer patients who currently have no suitable donor, potentially improving survival.
What could go wrong
This is a very early phase 1 trial with only 29 participants, so results may not apply broadly. There are significant risks including graft failure, severe infection, and graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, 310003, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact